A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Launched by THERATOCULAR BIOTEK CO. · May 20, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called MG-O-1002 eye drops for people over 45 who have a condition known as neovascular age-related macular degeneration (nAMD). This condition affects the central part of the retina, which can lead to vision loss. The trial will measure how well these eye drops can improve the thickness of the central macula, an important area for clear vision. The study has two parts: the first part is for individuals who have recently been diagnosed and haven't received any treatment yet, while the second part is for those who have already received injections of another medication called Aflibercept.

To participate in the trial, you need to be at least 45 years old and have a confirmed diagnosis of nAMD. In the first part, it's important that your study eye has not had any previous treatments for this condition, and your vision should be between 20/25 and 20/200. Participants will need to be able to use eye drops, either by themselves or with the help of a family member. Throughout the trial, participants will be monitored closely, and they will need to provide informed consent to ensure they understand the study and its requirements. If you think you might be eligible or are interested in joining, feel free to reach out for more information!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Part 1:
• • 1. Adults aged 45 years or older with a diagnosis of nAMD
• • 2. Diagnosis in the study eye of active, pathologic, newly diagnosed and treatment naïve (i.e., no previous anti-VEGF treatment or other surgery in the study eye)
• • 3. Visual acuity from 20/25 to 20/200 in the study eye
• • 4. Total lesion size (including neovascularization, blood) ≦12 disc areas (30.5 mm2) as assessed by Fluorescein Angiography.
• • 5. Demonstrate the ability, or have a family member who is willing and able to, instill topical ocular drops in the study eye.
• • 6. Ability to give written informed consent and comply with study procedures.
• Part 2:
• • 1. Adults aged 45 years or older with a diagnosis of nAMD.
• • 2. Participant with nAMD previously treated with 3 injections of Aflibercept within the preceding 4 months, and received the last injection within 30 to 21 days before visit 1 of this study.
• • 3. Demonstrate the ability, or have a family member who is willing and able to, instil topical ocular drops in the study eye.
• • 4. Ability to give written informed consent and comply with study procedures.
• Exclusion Criteria:
• Part 1:
• • 1. Prior use within the last 2 months, or a high possibility of requiring treatment with anti-VEGF therapy (except the study drug) in both eyes during the study.
• • 2. Abnormal regions identified by Fundus Autofluorescence (FAF) and Optical Coherence Tomography (OCT) involving the center of the fovea are caused by retinal pigment epithelium (RPE) atrophy, RPE tear, photoreceptor attenuation, or fibrosis/scar tissue.
• • 3. Significant retinal serous pigment epithelial detachment (PED) involving the fovea.
• • 4. History of, or current clinical evidence in the study eye of aphakia, diabetic macular edema, any ocular inflammation or infection, pathological myopia, retinal detachment, advanced glaucoma, and/or significant media opacity, including cataract.
• • 5. History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
• • 6. Uncontrolled hypertension despite the use of antihypertensive medications.
• • 7. Diagnosis of Type 1 or Type 2 diabetes.
• • 8. Use of medications that in the opinion of the Investigator could interfere with study results.
• • 9. Participation in any investigational drug or device study, systemic or ocular, within the past 3 months.
• • 10. Women who are pregnant or breast feeding.
• • 11. Women of child-bearing potential who are not using an effective form of birth control.
• • 12. Known serious allergies or hypersensitivity to the fluorescein dye used in angiography, or to the components of the MG-O-1002 formulation, or to topical anesthetics.
• • 13. In the opinion of the investigator, subject who is not suitable for or not likely be benefited from the study treatment.
• Part 2:
• • 1. More than 30 days between 3rd injection of Aflibercept and Visit 1.
• • 2. Patients who have received 3 injections of Aflibercept within the last 3 months and need continued treatment in the fellow eye.
• • 3. Significant retinal serous pigment epithelial detachment (PED), atrophy, or fibrosis/scar involving the fovea.
• • 4. History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
• • 5. Active intraocular inflammation or uveitis or scleritis or episcleritis in the study eye or ocular or periocular infection in either eye.
• • 6. Uncontrolled hypertension despite the use of antihypertensive medications.
• • 7. Diagnosis of Type 1 or Type 2 diabetes.
• • 8. Use of medications that in the opinion of the Investigator could interfere with study results.
• • 9. Participation in any investigational drug or device study, systemic or ocular, within the past 3 months.
• • 10. Women who are pregnant or breast feeding.
• • 11. Women of child-bearing potential who are not using an effective form of birth control.
• • 12. Known serious allergies or hypersensitivity to the fluorescein dye used in angiography, or to the components of the MG-O-1002 formulation, or to topical anesthetics.
• • 13. In the opinion of the investigator, subject who is not suitable for or not likely be benefited from the study treatment.